Oppenheimer Remains Bullish Ahead of Sonic Corp's (SONC) 4Q Report

Pre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...)

Today's Pre-Open Stock Movers

Galectin Therapeutics Inc. (NASDAQ: GALT) 48% LOWER; announced topline results from NASH-FX, its Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of GR-MD-02 in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis. This exploratory, single site, short-treatment (four months of therapy), randomized study did not meet its primary biomarker endpoint as measured by LiverMultiScan (LMS, Perspectum Diagnostics), a magnetic resonance imaging test that evaluates inflammation and fibrosis. The trial also did not meet secondary endpoints that measure liver stiffness as a surrogate for fibrosis,... More

Jefferies Cuts Price Target on Sonic Corp (SONC) to $28 Ahead of 4Q Report

Jefferies maintained a Hold rating on Sonic Corp (NASDAQ: SONC), and cut the price target to $28.00 (from $30.00), ahead of the company's 4Q earnings report. SONC preannounced F4Q system SSS of -2% vs. the consensus of +0.5%, with Company SSS of -3% coming... More

Sonic (SONC) volatility flat into reporting preliminary Q4 system-wide SSS down roughly 2%

Sonic Corp (NASDAQ: SONC) is recently down $1.86 to $25.58 in the premarket after reporting preliminary Q4 adjusted EPS 43c-45c, compared to consensus 48c. Option implied volatility index mean is at 42, compared to its 52-week range of 28 to 55, according to Livevol.

After-Hours Stock Movers 09/27: (SEED) (GALE) (CTAS) Higher; (GALT) (TPX) (NKE) Lower (more...)

Today's After-Hours Movers

Origin Agritech Limited (NASDAQ: SEED) 32.6% HIGHER; announced the company has entered into a definitive agreement to sell its proprietary China-based commercial corn seed production and distribution business for RMB 400 million (approximately USD $60 million) to Beijing Shihui Agricultural Development Co, Ltd.

Galectin Therapeutics Inc. (NASDAQ: GALT) 40% LOWER; announced topline results from NASH-FX, its Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of GR-MD-02 in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis. This exploratory, single site,... More

Sonic Corp (SONC) Prelim. Q4 EPS Falls Short of Consensus

Sonic Corp. (NASDAQ: SONC), the nation's largest chain of drive-in restaurants, today announced preliminary results for its fourth fiscal quarter ended August 31, 2016.

The company estimates that system-wide same-store sales for its fourth fiscal quarter decreased approximately 2.0%. Estimated same-store sales performance reflects a decrease of approximately 3.0% at company drive-ins and a decrease of approximately 1.8% at franchise drive-ins for the fourth fiscal quarter. Additionally, net income per diluted share is anticipated to be $0.51 to $0.53. Adjusted net income per diluted share is estimated to be $0.43 to $0.45 for the fourth... More